{'fraction_non_alphanumeric': 0.016, 'fraction_numerical': 0.0016, 'mean_word_length': 5.387755102040816, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mithramycin in the treatment of metastatic ewing's sarcoma

Five patients with progressive, metastatic Ewing's sarcoma were treated with infusions of mithramycin. Two had excellent regressions of their tumors; one patient has no clinical evidence of tumor more than 7 years after mithramycin was given. Patients who are resistant to cyclophosphamide may respond to mithramycin and vice versa. The exact role of mithramycin in patients with Ewing's sarcoma is not known. Further experimental trials are indicated with mithramycin alone and in combination both as adjunctive therapy and for the treatment of metastatic disease.